HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody responses to nuclear antigens

JOSEF S SMOLEN,¹ JOHN H KLIPPEL,⁴ EDWARD PENNER,² MORRIS REICHLIN,⁸ ALFRED D STEINBERG,⁴ THOMAS M CHUSED,⁵ OTHMAR SCHERAK,¹ WINFRIED GRANINGER,¹ ENGELBERT HARTTER,¹ CHRISTOPH C ZIELINSKI,¹ AXEL WOLF,¹ RICHARD J DAVEY,⁶ DEAN L MANN,⁷ AND WOLFGANG R MAYR³

From the ¹2nd Department of Internal Medicine, the ²1st Department of Gastroenterology, and the ³Institute of Blood Group Serology, University of Vienna, Vienna, Austria; the ⁴Arthritis and Rheumatism Branch, National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases National Institutes of Health, Bethesda, Maryland, USA; the ⁵Laboratory of Microbial Immunology, National Institute of Allergy and Infectious Diseases, Bethesda, and the ⁶Blood Bank, National Institutes of Health, Bethesda; the ⁷Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda; and the ⁸Arthritis and Immunology Laboratory, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA

SUMMARY HLA-DR antigens and autoantibodies to the nuclear or cytoplasmic antigens Ro/SSA, La/SSB, Sm, and RNP were determined in North American and Austrian patients with systemic lupus erythematosus (SLE). Analysis of the association of antibodies to these ribonucleic acid (RNA)-protein antigens with HLA-DR antigens showed that HLA-DR3 was related to the presence of anti-Ro/SSA or anti-La/SSB, or both. In contrast, anti-Sm or anti-RNP, or both were associated with HLA-DR4. HLA-DR5 was associated with absence of these autoantibodies. The data extend evidence for the complexity and heterogeneity of SLE. Moreover, they indicate that, in SLE, genes linked to those coding for HLA-DR antigens, are related to the specificity of autoantibody responses rather than to the primary immunological abnormalities of this disorder.

Key words: antinuclear antibodies, Ro, La, Sm, RNP.

The diversity of autoantibodies in patients with systemic lupus erythematosus (SLE) is unexplained. In addition to antibodies to deoxyribose nucleic acid (DNA), precipitating antibodies to a variety of nuclear antigens have been described.^{1,2} These antibodies are directed against ribonucleoprotein particles which contain small nuclear RNA. Among them, the most common are those to Ro (SSA) antigen. Antibodies to La (SSB) almost invariably occur together with antibodies to Ro/SSA.^{3,4}

Antibodies to Sm are currently regarded as the most specific, though insensitive, marker of SLE.

Antibodies to nuclear ribonucleoprotein (RNP) are also observed in SLE but they are present in much higher titres in sera from patients with mixed connective tissue disease (MCTD).⁵

Recent investigations have indicated that anti-Ro/La and anti-Sm/RNP represent two families of autoantibody systems.^{3,4,6-9} This evidence from molecular analyses has a biological correlate: SLE patients with anti-Ro may have distinct clinical features¹⁰⁻¹³ which are different from those of SLE patients with anti-Sm or anti-RNP.¹⁴⁻¹⁶ Moreover, non-SLE patients with anti-Ro or anti-La usually have primary Sjögren's syndrome, whereas non-SLE patients with anti-RNP primarily suffer from MCTD.^{1,2,5,17,18}

Immune responses to autoantigens, like those to conventional antigens, are controlled by the major

Accepted for publication 16 December 1986.
Correspondence to Dr Josef S Smolen, 2nd Department of Internal Medicine, University of Vienna, Garnisongasse 13, A-1090 Vienna, Austria.

histocompatibility complex (MHC).¹⁹ Several autoimmune disorders have been found associated with genes of the MHC, some even with two or more such genes,¹⁹ and SLE is one example.²⁰⁻²²

The reason for such associations has not been fully elucidated as yet. Searching for potential associations between autoantibody production and MHC genes in SLE, we have investigated patients with SLE for both HLA antigens and circulating antibodies to RNA-protein antigens. The results suggest that expression of these autoantibodies in SLE is controlled by genes closely linked to D locus alleles of the MHC and that these associations are different for different autoantibody specificities.

Patients, materials, and methods

PATIENT POPULATION

One hundred Caucasian patients (93 female, seven male) with systemic lupus erythematosus according to the American Rheumatism Association criteria^{23, 24} were studied; thirty six were American and 64 Austrian. The age range at the time of the study was 17-72 years.

DETERMINATION OF HLA ANTIGENS

Fourteen antigens governed by HLA-A, 17 by HLA-B, and five by HLA-C were determined using the standard National Institute of Health (NIH) microlymphocytotoxicity assay. Each antigen was identified by at least three separate sera. The sera used have been shown to bear the same specificities as the standard sera of the 4th to 8th Histocompatibility Workshops. Moreover, these sera did not contain antibodies to B cell antigens.

Reactivity was regarded as positive if at least three sera used to define a specific antigen lysed >80% of the cells. Six HLA-DR antigens (HLA-DR1-5 and 7) were analysed for HLA-DR typing by the two colour fluorescence method.²⁵ The antisera employed have been shown to bear the same specificities as those of the 7th to 9th Histocompatibility Workshops.

The data obtained in the patient population were compared with those of control populations. Control data for American Caucasians were taken from the data obtained at the 8th Histocompatibility Workshop.²⁶ Control data for the Austrians were obtained by local tissue typing of 450 healthy individuals (for HLA-A, B, C typing) or 125 healthy persons (for HLA-DR typing). Since the antigen frequencies in these latter control populations,²⁷ which were obtained using sera of the Histocompatibility Workshops, did not differ ($p>0.1$) from the frequencies in other Middle European populations²⁶ or from the Workshop data for American Cauca-

sians, data of healthy American and Austrian Caucasians were combined ($n=1270$) as control populations.²⁸

DETERMINATION OF ANTIBODIES TO RNA-PROTEIN ANTIGENS

All patients had antinuclear antibodies as determined by indirect immunofluorescence on mouse or rat liver sections. All but three patients had antibodies to double stranded DNA as determined by the Farr technique. Antibodies to RNA-protein antigens were analysed by immunodiffusion in Oklahoma (US patients) and by immunodiffusion and the Western blot technique in Vienna (US patients and Austrian patients) as previously described.^{29, 30} When discrepancies occurred results obtained by blotting were used for further analyses. The antibody specificities analysed were: anti-Sm, anti-RNP, anti-Ro/SSA, and anti-La/SSB.

STATISTICAL ANALYSIS

Statistical analysis of the HLA antigen frequencies was performed by χ^2 or Fisher's exact test²⁸; the values obtained were corrected for the number of antigen specificities investigated (p_c).^{28, 31}

Results

FREQUENCY OF HLA ANTIGENS IN SLE

The frequencies of HLA-DR antigens in the patient populations studied are shown in the first line of Table 1. When compared with control data ($n=1270$) there was a significantly increased frequency in patients with SLE of both HLA-DR2 and DR3 (DR2: 41% in SLE v 25% in controls, $p<0.0005$, $p_c<0.003$; DR3: 39% in SLE v 22% in controls, $p<0.0002$, $p_c<0.001$). As with the US and Austrian controls, frequencies of HLA antigens in Austrian and Caucasian US patients did not differ significantly from each other ($p>0.1$; data not shown), and the two populations were therefore combined.

CORRELATION BETWEEN HLA-DR ANTIGENS AND PRECIPITATING ANTIBODIES TO RNA-PROTEIN ANTIGENS

The distribution of autoantibodies to RNA-protein antigens is shown in Table 1 and related to HLA-DR antigens. This allowed for a detailed analysis of potential associations between the presence of MHC encoded antigens and the occurrence of particular types of precipitating antibodies. Patients were divided into four groups: (a) patients with anti-La (SSB), anti-Ro (SSA), or both (termed group I or 'anti-Ro/La'); (b) patients with anti-Sm, anti-RNP, or both (termed group II or 'anti-Sm/RNP'); (c) patients with anti-Ro and anti-S-

Table 1 Distribution of HLA-DR antigens and autoantibodies to RNA-protein antigens in 100 patients with SLE

Autoantibody Specificity	Patients group	n	DR1	DR2	DR3	DR4	DR5	DR7
—	All SLE	100	18	41	39	17	18	21
Anti-Ro/La*	I	32	5 (16%)†	15 (47%)	19 (59%)	2 (6%)	1 (3%)	6 (19%)
Anti-Sm/RNP*	II	12	4 (33%)	6 (50%)	2 (17%)	6 (50%)	1 (8%)	1 (8%)
Anti-Ro/Sm/RNP*	III	6	2 (33%)	3 (50%)	3 (50%)	1 (17%)	0 (0%)	1 (17%)
None*	IV	50	7 (14%)	17 (34%)	15 (30%)	8 (16%)	16 (32%)	13 (26%)
—	None	1270‡	258 (20%)	315 (25%)	274 (22%)	342 (27%)	255 (20%)	303 (24%)

*For detailed definition see text.

†Percentage of patients analysed in the respective line.

‡Frequencies in control population according to references 26 and 27.

and/or anti-RNP (termed group III or 'anti-Ro/Sm/RNP'); and (d) patients with none of the above (termed group IV or 'none' or 'no anti-Ro/Sm/RNP'). As discussed above, molecular analyses have shown close similarities between the Ro and the La antigens and between the Sm and the RNP antigens respectively.^{3 4 6-9} Therefore we sought to distinguish between antibody responses to these two different, non-cross-reactive nucleoprotein families. Since several patients had antibodies to both Ro/La and Sm/RNP we grouped them separately (group III) for the analyses.

ASSOCIATION OF DIFFERENT HLA-DR ANTIGENS WITH ANTIBODIES TO RO/LA AND SM/RNP

Nineteen of the 32 patients with anti-Ro/La (group I, 59%), but only 17 of 62 patients (groups II plus IV) without anti-Ro/La (27%) had HLA-DR3 (Table 1) ($p<0.002$, $p_c<0.015$). No other significant differences concerning the other HLA-DR antigens were observed between the two populations.

Next, HLA-DR antigen distributions were related to the presence of anti-Sm/RNP. Two interesting observations emerged: firstly, only two of these 12 patients (17%) had HLA-DR3, though 50% were positive for DR2; secondly, in half of these patients, but in only 12% of all patients without anti-Sm/RNP (groups I plus IV), HLA-DR4 was present ($p\leq 0.01$, $p_c<0.05$). In addition, 33% of both group II and group III patients, but only 13% and 14% respectively, of group I and group IV patients, had HLA-DR1; this difference was not significant statistically. When the frequency of DR1 and DR4 were considered together, nine of 12 patients with anti-Sm-RNP (75%), but only 22 of 82 patients without anti-Sm/RNP (27%), had DR1 or DR4, or both

($p<0.001$, $p_c<0.02$, corrected for the number of possible pairs of DR antigens). Moreover, 50% of the patients with both anti-Ro and anti-Sm/RNP (group III) had HLA-DR1 or DR4, or both.

LACK OF ASSOCIATION OF SLE WITH HLA-DR ANTIGENS IN PATIENTS WITHOUT ANTIBODIES TO RNA-PROTEIN ANTIGENS

When the frequency of HLA-DR antigens in the 50 patients without antibodies to Ro, La, Sm, or RNP (Table 1, group IV) was compared with that of healthy controls the differences for all HLA-DR antigens, including HLA-DR2 and DR3, lacked significance. In contrast, HLA-DR3 was markedly increased ($p_c<0.00001$) in anti-Ro/La (but not anti-Sm/RNP) patients, and HLA-DR2, present in approximately 50% of all group I, II, and III patients, was also increased in frequency when compared with the control population ($p_c<0.002$). Of interest, 32% of the patients without antibodies to Ro, La, Sm, or RNP were found to have HLA-DR5 as opposed to only 4% of individuals with at least one of these autoantibodies (Table 1, $p=0.0004$, $p_c<0.0025$).

Discussion

In this Caucasian population of North American and Middle European SLE patients a significantly increased frequency of HLA-DR3 and of HLA-DR2 was observed. These significant associations, however, were seen only among patients with antibodies to the RNA-protein antigens Ro, La, Sm, or RNP. This lack of association in anti-Ro/La/Sm/RNP negative patients was not due a low patient number, since the antibody negative group comprised exactly half of the total study population. Rather, these data

indicate that the mechanisms underlying the pathogenesis of SLE disease are not necessarily MHC associated.

Analysis of the relation between antibodies to RNA-protein and HLA antigens showed that the association of HLA-DR3 with SLE in the total patient population was predominantly due to its increased frequency in one subgroup of patients, namely those with the autoantibodies anti-Ro/SSA and La/SSB. In contrast, DR3 frequencies were low in patients with anti-Sm or anti-RNP antibodies, or both, and, as stated above, were not significantly increased in patients without precipitating antibodies to RNA-nucleoprotein antigens. Thus HLA-DR3 apparently does not represent a gene that predisposes to the disease in general but rather to a subset of the disease characterised by the production of a specific autoantibody. This interpretation is indirectly strengthened by the known relationship between HLA-DR3 and primary sicca syndrome,³²⁻³⁶ in which anti-Ro/SSA is also a serological hallmark.^{1 2 18} Moreover, it agrees with previous observations of the occurrence of HLA-DR3 and anti-Ro/SSA in SLE^{10 11 34 37-39} and LE subsets with characteristic clinical features associated with the presence of anti-Ro/SSA.¹⁰⁻¹³ When comparing our data with those of these other studies, the important common determinant is the association of anti-Ro/La with HLA-DR3, which has previously been observed in both SLE³⁷⁻³⁹ and primary Sjögren's syndrome.³⁴⁻³⁶ We could not find the previously reported^{38 39} association of anti-Ro with HLA-DR2. Moreover, in contrast with these authors, and as already previously reported by the University of Vienna and NIH groups separately,^{20 22} the present common study again confirms the highly increased frequency of HLA-DR3 in a much larger SLE population. Finally, in contrast with the findings of Alvarellos *et al*,³⁹ our study showed no association of HLA-DR antigens with either frequency or levels of antinative DNA antibodies (data not shown). In additional analyses the presence of anti-Sm or RNP, or both, has been found to be significantly associated with HLA-DR4 and somewhat more strongly with the presence of DR4 or DR1, or both. Although this finding should not be overemphasised, these data and the low frequency of HLA-DR3 in this group of patients, which was also noted by Alvarellos *et al*,³⁹ indicate that the expression of anti-Sm/RNP is genetically distinctly different from that of anti-Ro/La. According to our observations, patients having antibodies to both Ro and Sm/RNP tended to be positive for the DR antigens associated with each antibody specificity separately, namely DR3 and/or DR4 or DR1. It is of particular interest that the molecular

structures of the related antigens Ro and La differ from the structures of the related antigens Sm and RNP, and that—as also seen in this study—anti-La almost always occurs together with anti-Ro, whereas anti-Sm very often is accompanied by anti-RNP.^{3 4 6-9} There is one report on the association of anti-RNP with HLA-DR1 in patients with mixed connective tissue disease,⁴⁰ a further indication of different genetic association when compared with anti-Ro.

Not every patient with a specific HLA-DR antigen expressed the antibodies to RNA-protein antigens. This indicates that there is either heterogeneity of the respective DR genes in the patient population or, more likely, that the genes related to the production of the specific autoantibodies are not identical with but only linked to the respective DR genes.

Further analyses showed that HLA-DR5 was related to the absence of the precipitating antibodies anti-Ro/SSA, anti-La/SSB, anti-Sm, and anti-RNP, and thus appeared to 'protect' against their expression. On the other hand, when compared with the control population the frequency of HLA-DR2 was significantly increased in patients with, but not in those without precipitating antibodies to Ro, La, Sm, or RNP. It is therefore tempting to speculate that genes linked to HLA-DR2 cooperate with genes linked to other DR antigens in the expression of specific autoantibodies in SLE. Finally, analyses of correlations between HLA-A, B, and C antigens and autoantibody specificities did not show significant association except of HLA-B8 with anti-Ro/La, which did not exceed the association of HLA-DR3 (data not shown).

Our findings suggest that the association of HLA antigens with autoimmune disease reflects the secondary role of immune response genes in defining which autoantigens will be recognised rather than a connection with the underlying primary immunoregulatory abnormality. In this regard, it is pertinent and in accordance with our conclusions that increased frequencies of particular HLA antigens have not been observed in studies of twins or families affected by SLE; rather, similarities of clinical and serological features have been found.^{41 42} Thus the predisposition to autoimmunity may reside in the inheritance of 'autoimmunity genes' which may be different in individuals with different autoimmune disorders;⁴³⁻⁴⁵ HLA-D region genes may then modify the expression of the disorder.

Our results in human SLE are quite analogous to those of Shirai and colleagues in New Zealand mice. These investigators have shown that in the lupus-

prone (NZB×NZW) F1 hybrids it is the H-2^Z haplotype of NZW that facilitates the production of several characteristic antibodies and that this effect is independent of the underlying primary immunological abnormality.⁴⁶

Taken together, the data presented provide evidence that SLE can be divided into several genetically distinct subgroups by HLA phenotyping and by determination of precipitating antibodies to RNA-protein antigens. Different autoantibody specificities are linked to different D locus genes of the MHC or to related genes. None of the MHC associated genes appears to be generally associated with SLE disease. The data thus speak for a pronounced immunogenetic heterogeneity of SLE with MHC control of the expression of certain serological markers. We would anticipate similar genetic heterogeneity of the underlying immunoregulatory abnormalities in SLE. These conclusions make the continued search for the genetic and environmental causes as well as for the pathogenesis of this multifaceted disorder even more challenging.

Supported by grants from the Fonds zur Förderung der wissenschaftlichen Forschung (P 4872), the Medical Foundation of the Mayor of Vienna, and the Federal Ministry for Science and Research (49.340/84).

References

- 1 Tan E M. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. *Adv Immunol* 1982; **33**: 167–240.
- 2 Reichlin M. In: Kelley W N, Harris E D, Ruddy S, Sledge C B, eds. *Textbook of rheumatology*. Philadelphia: Saunders, 1985: 690–706.
- 3 Harley J B, Yamagata H, Reichlin M. Anti-La/SSB antibody is present in some normal sera and is coincident with anti-Ro/SSA precipitins in systemic lupus erythematosus. *J Rheumatol* 1984; **11**: 309–14.
- 4 Maddison P J, Skinner R P, Vlachoyiannopoulos P, Brennan D M, Hough D. Antibodies to nRNP, Sm and La (SSB) detected by ELISA: their specificity and interrelations in connective tissue diseases. *Clin Exp Immunol* 1985; **62**: 337–45.
- 5 Sharp G C, Irvin W S, May C M, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective tissue disease, systemic lupus erythematosus and other rheumatic disease. *N Engl J Med* 1976; **295**: 1149–53.
- 6 Hendrick J P, Wolin S, Rinke J, Lerner M R, Steitz J A. Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells. *Mol Cell Biol* 1981; **1**: 1138–49.
- 7 Takano M, Golden S S, Sharp G C, Agris P F. Molecular relationship between two nuclear antigens, ribonucleoprotein and Sm: purification of active antigens and their biochemical characterization. *Biochemistry* 1981; **21**: 5929–35.
- 8 Lerner E A, Lerner M R, Janeway C A Jr, Steitz J A. Monoclonal antibodies to nucleic acid-containing cellular constituents as probes for molecular biology and autoimmune disease. *Proc Natl Acad Sci USA* 1981; **78**: 2737–41.
- 9 Petterson I, Hinterberger M, Mimori M, Gottlieb E, Steitz J A. The structure of mammalian small ribonucleoproteins: identification of multiple protein components reactive with anti (U1) RNP and anti-Sm antibodies. *J Biol Chem* 1984; **259**: 5907–14.
- 10 Maddison P J, Provost T T, Reichlin M. Serological findings in patients with 'ANA-negative' systemic lupus erythematosus. *Medicine (Baltimore)* 1981; **60**: 87–94.
- 11 Sontheimer R D, Maddison P J, Reichlin M, Jordan R E, Stastny P, Gilliam J N. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. *Ann Intern Med* 1982; **97**: 664–71.
- 12 Provost T T, Arnett F C, Reichlin M. Homozygous C2 deficiency, lupus erythematosus and anti-Ro (SSA) antibodies. *Arthritis Rheum* 1983; **26**: 1279–82.
- 13 Kephart D C, Hood A F, Provost T T. Neonatal lupus erythematosus: new serologic findings. *J Invest Dermatol* 1981; **77**: 331–3.
- 14 Winfield J B, Brunner C M, Koffler D. Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. *Arthritis Rheum* 1978; **21**: 289–94.
- 15 Maddison P J, Mogavero H, Reichlin M. Patterns of clinical disease associated with antibodies to nuclear ribonucleoprotein. *J Rheumatol* 1978; **5**: 407–11.
- 16 Smolen J S, Morimoto C, Steinberg A D, et al. Systemic lupus erythematosus: delineation of subpopulations by clinical, serologic, and T cell subset analysis. *Am J Med* 1985; **289**: 139–46.
- 17 Alspaugh M A, Tan E M. Antibodies to cellular antigens in Sjögren's syndrome. *J Clin Invest* 1975; **55**: 1067–73.
- 18 Alspaugh M, Maddison P. Resolution of the identity of certain antigen-antibody systems in systemic lupus erythematosus and Sjögren's syndrome: an interlaboratory collaboration. *Arthritis Rheum* 1979; **22**: 796–8.
- 19 Van Rood J J, De Vries R R P, Bradley B A. Genetics and biology of the HLA system. In: Dorf D M, ed. *The role of the major histocompatibility complex in immunobiology*. Chichester: Wiley, 1981: 59–113.
- 20 Reinertsen J L, Klippel J H, Johnson A H, Decker J L, Steinberg A D, Mann D L. B lymphocyte alloantigens associated with systemic lupus erythematosus. *N Engl J Med* 1978; **299**: 515–8.
- 21 Gibofsky A, Winchester R J, Patarroyo M, Fotino M, Kunkel H G. Disease associations of the Ia-like human alloantigens: contrasting patterns in rheumatoid arthritis and systemic lupus erythematosus. *J Exp Med* 1978; **148**: 1728–32.
- 22 Scherak O, Smolen J S, Mayr W R. HLA-DRw3 and systemic lupus erythematosus. *Arthritis Rheum* 1980; **23**: 954–7.
- 23 Cohen A S, Reynolds W E, Franklin E C, et al. Preliminary criteria for classification of systemic lupus erythematosus. *Bull Rheum Dis* 1971; **21**: 643–8.
- 24 Tan E M, Cohen A S, Fries J F, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982; **25**: 1271–7.
- 25 Van Rood J J, van Leeuwen A, Ploem J S. Simultaneous detection of two cell populations by two colour fluorescence and application to the recognition of B-cell determinants. *Nature* 1976; **262**: 795–7.
- 26 Baur M P, Danilovs J A. Population analysis of HLA-A, B, and C, DR and other genetic markers. In: Terasaki P I, ed. *Histocompatibility testing*. London: University of California Press, 1980: 955–62.
- 27 Smolen J S, Gangl A, Polterauer P, Menzel J, Mayr W R. HLA antigens in inflammatory bowel disease. *Gastroenterology* 1982; **82**: 34–8.
- 28 Svejgaard A, Jersild C, Staub Nielsen L, Bodmer W F. HLA- A antigens and disease. Statistical and genetical considerations. *Tissue Antigens* 1974; **4**: 95–105.
- 29 Penner E, Kindas-Mügge I, Hitchman E, Sauermann G. Nuclear antigens recognized by antibodies present in liver disease sera. *Clin Exp Immunol* 1986; **63**: 428–33.
- 30 Clark G, Reichlin M, Tomasi T B. Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus. *J Immunol* 1969; **102**: 117–22.
- 31 Grumet F C. HLA and disease associations. *Transplant Proc* 1977; **9**: 1839–44.

- 32 Chused T M, Kassan S S, Opelz G, Moutsopoulos H M, Terasaki P I. Sjögren's syndrome associated with HLA-Dw3. *N Engl J Med* 1977; **296**: 895-7.
- 33 Moutsopoulos H M, Mann D L, Johnson A H, Chused T M. Genetic differences between primary and secondary sicca syndrome. *N Engl J Med* 1979; **301**: 761-3.
- 34 Manthorpe R, Teppo A M, Bendixen G, Wegelius O. Antibodies to SS-B in chronic inflammatory connective tissue disease. *Arthritis Rheum* 1982; **25**: 662-7.
- 35 Harley J B, Alexander E L, Bias W B, et al. Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjögren's syndrome *Arthritis Rheum* 1986; **29**: 196-206.
- 36 Molina R, Provost T T, Arnett F, et al. Primary Sjögren's syndrome in men. *Am J Med* 1986; **80**: 23-31.
- 37 Bell D A, Maddison P J. Serologic subsets in systemic lupus erythematosus: an examination of autoantibodies in relationship to clinical features of disease and HLA antigens. *Arthritis Rheum* 1980; **23**: 1268-73.
- 38 Ahearn J M, Provost T T, Dorsch C A, Stevens M B, Bias W B, Arnett F C. Interrelationships of HLA-DR, MB and MT phenotypes, autoantibody expression, and clinical features in systemic lupus erythematosus. *Arthritis Rheum* 1982; **25**: 1031-40.
- 39 Alvarellos A, Ahearn J M, Provost T T, et al. Relationships of HLA-DR and MT antigens to autoantibody expression in systemic lupus erythematosus. *Arthritis Rheum* 1983; **26**: 1533-5.
- 40 Stahl N, Johnson A H, Decker J L, Sharp G C, Mann D L. B lymphocyte antigens in mixed connective tissue disease. [Abstract]. *Arthritis Rheum* 1980; **23**: 571.
- 41 Cleland L G, Bell D A, Williams M, Saurino B C. Familial lupus. Family studies of HLA and serologic findings. *Arthritis Rheum* 1978; **21**: 183-91.
- 42 Reinertsen J L, Klippel J H, Johnson A H, Steinberg A D, Decker J L, Mann D L. Family studies of B lymphocyte alloantigens in systemic lupus erythematosus. *J Rheumatol* 1982; **9**: 253-62.
- 43 Raveche E S, Novotny E A, Hansen C T, Tjio J H, Steinberg A D. Genetic studies in NZB mice. V. Recombinant inbred lines demonstrate that separate genes control autoimmune phenotype. *J Exp Med* 1981; **153**: 1187-97.
- 44 Bias W B, Meyers D A, Conley C L, Reveille J D, Wilson R W, Arnett F C. Evidence that autoimmunity is a Mendelian dominant trait [Abstract]. *Am J Hum Genet* 1983; **35**: 77A.
- 45 Smolen J S, Steinberg A D. Disorders of immune regulation. In: Twomey J J, ed. *The pathophysiology of human immunologic disorders*. Baltimore: Urban and Schwarzenberg, 1982: 173-97.
- 46 Yoshida H, Kohno A, Ohta K, Hirose S, Maruyama N, Shirai T. Genetic studies of autoimmunity in New Zealand mice. III. Associations among anti-DNA antibodies, NTA, and renal disease in (NZB×NZW) F1×NZW backcross mice. *J Immunol* 1981; **127**: 433-7.